« IGFR Therapies Wipe Out. And They're Not Alone. |
| Another Prospective Alzheimer's Trial »
October 11, 2012
GSK Opens Up Its Trial Data
GlaxoSmithKline took an unusual step today: they announced that they're opening up clinical trial data:
"GSK is fully committed to sharing information about its clinical trials. It posts summary information about each trial it begins and shares the summary results of all of its clinical trials – whether positive or negative – on a website accessible to all. Today this website includes almost 4,500 clinical trial result summaries and receives an average of almost 10,000 visitors each month. The company has also committed to seek publication of the results of all of its clinical trials that evaluate its medicines – regardless of what the results say – to peer-reviewed scientific journals.
Expanding further on its commitments to openness and transparency, GSK also announced today that the company will create a system that will enable researchers to access the detailed anonymised patient-level data that sit behind the results of clinical trials of its approved medicines and discontinued investigational medicines. To ensure that this information will be used for valid scientific endeavour, researchers will submit requests which will be reviewed for scientific merit by an independent panel of experts and, where approved, access will be granted via a secure web site. This will enable researchers to examine the data more closely or to combine data from different studies in order to conduct further research, to learn more about how medicines work in different patient populations and to help optimise the use of medicines with the aim of improving patient care."
I very much applaud this step, and I very much hope that the rest of the industry follows suit. We're getting a lot of flack - and we deserve it - for the way that we handle clinical trial data, with accusations of cherry-picking, data-burying, and all the associated sins. (Ben Goldacre has a book out on the drug industry, which I'm going to read more of before posting on, and he's taken the industry to task on this very point in it). The only cure for this will be to open the books as much as possible - saying "Trust us" will not cut it, and (unfortunately), neither will trying to say "None of your business".
Here's a look at this idea from John Carroll at FierceBiotech. So, Pfizer, Novartis, Merck, all the rest of you? What's the response?
+ TrackBacks (0) | Category: Clinical Trials | Why Everyone Loves Us
POST A COMMENT
- RELATED ENTRIES
- AstraZeneca's Move To Hot, Happening Cambridge
- Stealing A Compound, To Set Up in China
- Tecfidera's Price
- Novartis Loses the Glivec Patent Fight in India
- ChemBark Closing Down (Update: Not Really!)
- Fake Journals - But They'd Like Real Money
- Chemical Probes Versus Drugs
- Two New Books